
A

pCXCL7	S	D	L	Y	A	E	L	R	C	M	C	I	K	T	T	S	-	G	I	H	P	K	N	I	Q	S
pCXCL1	A	S	V	A	T	E	L	R	C	Q	C	L	Q	T	L	Q	-	G	I	H	P	K	N	I	Q	S
pCXCL2	A	P	L	A	T	E	L	R	C	Q	C	L	Q	T	L	Q	-	G	I	H	L	K	N	I	Q	S
pCXCL3	A	S	V	V	T	E	L	R	C	Q	C	L	Q	T	L	Q	-	G	I	H	L	K	N	I	Q	S
pCXCL8	P	R	S	A	K	E	L	R	C	Q	C	I	K	T	Y	S	K	P	F	H	P	K	F	I	K	E






FIGURE 1



D
Control 35B11-8 12A10-13
E
Cytokine amount (ng/mg prot.)
18
12
6
1.6
1.2
0.8
0.4
0
Control
12A10-13
35B11-8
*
**
CXCL1
CXCL7
CXCL8
VEGF

FIGURE 1



3
2.5
2
1.5
1
0.5
0
Bioluminescence (photons/s x 10^7)
CONT
AC CXCL7
AC CXCL8
AC CXCL7+ AC CXCL8
0
10
20
30
40
50
60
70
80
90
Days post injection
*
*
*
*
*
*
*

FIGURE 2



800
700
600
500
400
300
200
100
0
Tumor size (mm3)
CONT
anti CXCL1, 7, 8
12A10-13
35B11-8
0
10
20
30
40
50
60
70
Days post injection
*
**
***
*
**
***
*
**
***

FIGURE 3

Kd (nM)	CXCL1	CXCL3	CXCL7	CXCL8
12A10-13	15.6	64.5	3.3	44.3
35B11-8	11.8	247	4.99	19.9


Kd (nM)	CXCL1	CXCL3	CXCL7	CXCL8
AC 1	5.48			
AC 1,2,3	15.3	29.2		
AC 7			7.3	
AC 8				20.4

Ka (x M10Exp8)	CXCL1	CXCL3	CXCL7	CXCL8
12A10-13	63,9	15,5	3.03	22.6
35B11-8	84,7	404	2.01	50.3

Ka (x M10Exp8)	CXCL1	CXCL3	CXCL7	CXCL8
AC 1	1.82			
AC 1,2,3	65.36	34.2		
AC 7			1.37	
AC 8				49

FIGURE 4

Antibodies 35B11-8 : **IgG1**



IgG1 **Positive control** **Light chain κ**

Antibodies12A10-13 : **IgG2c**



Positive control

Light chain κ **IgG2c**

FIGURE 5



A
Overall survival/CXCL1
Probability overall survival
Intra-tumor CXCL1<Third quartile
p = 0.03
Intra-tumor CXCL1 > Third quartile
Months
B
Overall survival/CXCL7
Probability overall survival
Intra-tumor CXCL7<First quartile
p = 0.0023
Intra-tumor CXCL7 > First quartile
Months
C
Overall survival/CXCL8
Probability of overall survival
Intra-tumor CXCL8 < median
Intra-tumor CXCL8 > median
p = 0.08
Months

FIGURE 6

Variable	Description	HR [95%CI]	Log-Rank
Clinical parameters			
Age	Per year	1.03 [0.97-1.1]	0.29
Sex	Male	1	0.33
	Female	0.55 [0.16-1.9]	-
Previous Cancer	No	1	0.61
	Yes	1.50 [0.33-6.4]	-
Metastasis at diagnosis	No	1	$<10^{-3}$
	Yes	6.4 [2.5-17]	-
Fuhrman stage (group)	1/2	1	0.001
	3/4	7.80 [1.8-34]	-
Biological parameters			
VEGF (V-Vb)	Per Unit	1 [0.99-1]	0.26
CXCL1	Per Unit	2.47 [1.17-5.22]	0.017
CXCL7	Per Unit	20.20 [3.12-130.5]	0.0015
CXCL8	Per unit	1.15 [0.77-1.68]	0.49

FIGURE 7

Variable	Description	HR [95%CI]	Log-Rank
Clinical parameters			
Metastasis at diagnosis	No	1	0.0005
	Yes	8.09 [2.52-26]	-
Fuhrman stage (group)	1/2	1	0.007
	3/4	7.84 [1.74-35.18]	-
Biological parameters			
CXCL1	Per Unit	2.34 [0.97-5.7]	0.059
CXCL7	Per Unit	8.46 [1.53-46.62]	0.014

FIGURE 8



A
Lesion size (mm³)
500
400
300
200
100
0
*
*
VEH
12A
35B
B
Lesion leakage score
3
2.5
2
1.5
1
0.5
0
**
*
VEH
12A
35B

FIGURE 9




FIGURE 9